Core Insights - The strategic partnership between Yuansong Group and Chongshan Biotechnology has led to the launch of the world's first collagen product derived from bovine tendons, named "Jiaoyuan Angel," which received Class III medical device registration approval from the National Medical Products Administration on December 10, 2025 [1][3] - The collagen market in China has reached a scale of 200 billion, with projections to grow to 500 billion by 2030, indicating significant growth potential in the industry [3] Product Advantages - "Jiaoyuan Angel" features a high concentration of medical collagen at 45 mg/ml, ensuring strong support [5] - The product is made from high-purity bovine tendon collagen, which guarantees the integrity of the raw material [5] - Advanced application technology allows for precise subcutaneous implantation, providing deeper support for the skin [5] - The development team overcame several technical challenges, establishing 45 mg/ml as the optimal concentration to balance collagen network formation and safety [5] - The product maintains biological activity and structural integrity through meticulous production processes [5] Market Trends - The introduction of "Jiaoyuan Angel" is expected to shift the focus of collagen applications from immediate filling effects to a trend of nutritional tightening in the industry [7] - Yuansong Group has established a strong presence in the medical aesthetics sector with several successful products, positioning itself as a market leader [7] - Analysts predict that "Jiaoyuan Angel" could capture significant market share quickly, potentially becoming a dark horse in the medical aesthetics market by 2026 [7]

Core Insights - The strategic partnership between Yuansong Group and Chongshan Biotechnology has led to the launch of the world's first collagen product derived from bovine tendons, named "Jiaoyuan Angel," which received regulatory approval on December 10 [1][3] - The collagen market has reached a scale of 200 billion and is projected to grow to 500 billion by 2030, indicating significant growth potential in the industry [3] Product Advantages - "Jiaoyuan Angel" features a high medical collagen concentration of 45 mg/ml, ensuring strong support [5] - The product uses collagen extracted from bovine tendons, ensuring high purity and structural integrity [5] - Advanced application technology allows for precise subcutaneous implantation, providing deeper network support for the skin [5] - The company has addressed industry challenges, establishing 45 mg/ml as the optimal concentration to balance efficacy and safety [5] Market Positioning - The collaboration signifies an upgrade in the synergy between clinical institutions and research enterprises, aiming to redefine the application of collagen in the market [6] - The focus is shifting from "volume enhancement" to "nutritional tightening," which is expected to become the mainstream trend in the collagen market [8] - Yuansong Group has previously launched several successful products in the medical beauty sector, positioning itself as a market leader [8] - "Jiaoyuan Angel" is anticipated to capture significant market share and potentially become a dark horse in the medical beauty market by 2026 due to its technological advantages and promotional capabilities [8]

Core Insights - The world's first collagen product derived from beef tendon will be launched by Yuansong on January 2, marking a significant development in the collagen market [1] - Yuansong Group has formed a strategic partnership with Chongshan Biotechnology to combine their technological advantages, aiming to shift the collagen field from "volume enhancement" to "nutritional tightening" [1] - The collagen market, currently valued at 200 billion, is projected to reach 500 billion by 2030, driven by applications in medical, beauty, and health sectors [1] Company Developments - Chongshan Biotechnology's "Jiaoyuan Angel," the first beef tendon collagen implant, received approval from the National Medical Products Administration on December 10 [1] - With the approval of Jiaoyuan Angel, the number of collagen products with Class III medical device certification in China has increased to 15, although only one-third of these products have become mainstream [1] - Chongshan's chairman highlighted that Jiaoyuan Angel stands out due to its redefined core dimensions in ingredient concentration, material source, and application technology [1] Industry Trends - The collaboration between Yuansong Group and Chongshan Biotechnology signifies an upgrade in the collaborative model between clinical institutions and research enterprises [1] - The new product is not just an addition but is intended to create a comprehensive treatment plan that integrates anti-aging medicine, natural aesthetics, and material science [1]